Abstract
Expert Rev. Anticancer Ther. 13(1), 5–8 (2013) “…T-DM1 provides high therapeutic potential, and can be expected to become a new standard treatment option for women with advanced, HER2-positive breast cancer who progress under treatment with trastuzumab and a taxane or develop disease progression after completion of this treatment.”
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
